Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS – Get Free Report) and SeaStar Medical (NASDAQ:ICU – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
12.4% of Senseonics Holdings, Inc. Common Stock shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are owned by insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Senseonics Holdings, Inc. Common Stock and SeaStar Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senseonics Holdings, Inc. Common Stock | $48.55 million | 6.05 | -$69.11 million | ($2.23) | -3.15 |
| SeaStar Medical | $1.23 million | 10.67 | -$12.15 million | ($4.80) | -0.68 |
SeaStar Medical has lower revenue, but higher earnings than Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Senseonics Holdings, Inc. Common Stock and SeaStar Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senseonics Holdings, Inc. Common Stock | -225.09% | -189.06% | -88.90% |
| SeaStar Medical | -828.62% | -146.29% | -96.48% |
Volatility & Risk
Senseonics Holdings, Inc. Common Stock has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Senseonics Holdings, Inc. Common Stock and SeaStar Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senseonics Holdings, Inc. Common Stock | 1 | 1 | 4 | 0 | 2.50 |
| SeaStar Medical | 1 | 0 | 1 | 0 | 2.00 |
Senseonics Holdings, Inc. Common Stock presently has a consensus price target of $17.20, indicating a potential upside of 145.01%. SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 143.90%. Given Senseonics Holdings, Inc. Common Stock’s stronger consensus rating and higher possible upside, research analysts plainly believe Senseonics Holdings, Inc. Common Stock is more favorable than SeaStar Medical.
Summary
Senseonics Holdings, Inc. Common Stock beats SeaStar Medical on 10 of the 14 factors compared between the two stocks.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
About SeaStar Medical
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Receive News & Ratings for Senseonics Holdings Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
